Altris AI Image Management System

Altris, Inc. (brand Altris AI) is headquartered in Chicago, Illinois, with R&D centers in Kyiv and Malaga. Research began in 2017 and the company was incorporated in April 2018, building AI for retinal OCT interpretation.

Altris IMS is an image management system working with 9 OCT manufacturers. AI modules cover geographic atrophy, dry and wet AMD, diabetic retinopathy, OCT fluid and glaucoma analysis, with a severity cube, patient filtering flags, longitudinal tracking and PDF reports. It targets ophthalmology, optometry and pharma research, and claims 500+ eye care businesses.

• Multi-pathology AI: Covers GA, dry and wet AMD, DR, OCT fluid and glaucoma.
• Severity cube: Visualizes pathology severity across the OCT volume.
• Flags patient filter: Searches patient cohorts by biomarkers and pathologies.
• Longitudinal analysis: Tracks changes between visits.
• Glaucoma tools: GCC asymmetry analysis and early risk alerts.
• Custom PDF reports: Generates reports for referral and records.

Private eye hospitals in Vietnam can speed up OCT reading for AMD and glaucoma follow-up. Optical chains with OCT can triage patients for referral. Research groups can analyze OCT cohorts with research-use models.

Vendor-neutral across 9 OCT manufacturers, so clinics keep existing devices.

Detects dozens of retinal pathologies and biomarkers to support faster OCT review.

Longitudinal analysis tracks disease progression over visits.

Offers a 2-week free trial mention on the site and monthly contact options.

OCT has become routine in eye clinics and optometry chains, and AI interpretation helps non-specialists triage retina disease. In Vietnam, private eye hospitals and optical chains adding OCT are potential users.

Chicago, Illinois, USA; incorporated April 2018. CE mark July 2019 and FDA 510(k) Class II for Altris IMS in September 2023; AI models are for research and decision support in the US. Health Canada approval March 2026. Partnership with Huvitz since May 2019.